1. Home
  2. TYRA vs MLCO Comparison

TYRA vs MLCO Comparison

Compare TYRA & MLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$25.94

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Melco Resorts & Entertainment Limited

MLCO

Melco Resorts & Entertainment Limited

HOLD

Current Price

$5.62

Market Cap

2.2B

ML Signal

HOLD

Company Overview

Basic Information
Metric
TYRA
MLCO
Founded
2018
2003
Country
United States
Hong Kong
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Hotels/Resorts
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.2B
IPO Year
2021
2006

Fundamental Metrics

Financial Performance
Metric
TYRA
MLCO
Price
$25.94
$5.62
Analyst Decision
Strong Buy
Buy
Analyst Count
11
5
Target Price
$47.50
$10.10
AVG Volume (30 Days)
732.5K
2.1M
Earning Date
05-06-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$5.42
Revenue Next Year
N/A
$4.37
P/E Ratio
N/A
$12.16
Revenue Growth
N/A
N/A
52 Week Low
$8.98
$5.19
52 Week High
$40.65
$10.15

Technical Indicators

Market Signals
Indicator
TYRA
MLCO
Relative Strength Index (RSI) 26.61 49.39
Support Level $24.88 $5.27
Resistance Level $31.57 $5.71
Average True Range (ATR) 1.84 0.21
MACD -0.68 0.03
Stochastic Oscillator 7.40 48.85

Price Performance

Historical Comparison
TYRA
MLCO

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About MLCO Melco Resorts & Entertainment Limited

Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs' electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 84% from Macao, with the rest from overseas as of 2025.

Share on Social Networks: